1h Free Analyst Time
Global Hepatitis C Drugs Market 2021-2025Speak directly to the analyst to clarify any post sales queries you may have.
The publisher has been monitoring the hepatitis C drugs market and it is poised to grow by $ 252.89 mn during 2021-2025 progressing at a CAGR of 1% during the forecast period. The report on hepatitis C drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing demand for direct-acting antivirals and rising number of patient support initiatives. In addition, increasing demand for direct-acting antivirals is anticipated to boost the growth of the market as well.
The hepatitis C drugs market analysis includes product segments and geographical landscapes.
The hepatitis C drugs market is segmented as below:
By Product
- Combination therapy
- Monotherapy
By Geographical Landscapes
- North America
- Europe
- Asia
- ROW
This study identifies the high prevalence of hepatitis C as one of the prime reasons driving the hepatitis C drugs market growth during the next few years.
The report on hepatitis C drugs market covers the following areas:
- Hepatitis C drugs market sizing
- Hepatitis C drugs market forecast
- Hepatitis C drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatitis c drugs market vendors that include AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., and Vertex Pharmaceuticals Inc. Also, the hepatitis c drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Exhibit
Executive Summary
The publisher recognizes the following companies as the key players in the global hepatitis c drugs market: AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., and Vertex Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is high prevalence of hepatitis C .'
According to the report, one of the major drivers for this market is the increasing demand for direct-acting antivirals.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Co.
- Cipla Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Vertex Pharmaceuticals Inc.
